160 related articles for article (PubMed ID: 8306246)
1. Overview of radiation myelotoxicity secondary to radioimmunotherapy using 131I-Lym-1 as a model.
DeNardo GL; DeNardo SJ; Macey DJ; Shen S; Kroger LA
Cancer; 1994 Feb; 73(3 Suppl):1038-48. PubMed ID: 8306246
[TBL] [Abstract][Full Text] [Related]
2. Application of the linear-quadratic model to myelotoxicity associated with radioimmunotherapy.
Wilder RB; DeNardo GL; Sheri S; Fowler JF; Wessels BW; DeNardo SJ
Eur J Nucl Med; 1996 Aug; 23(8):953-7. PubMed ID: 8753685
[TBL] [Abstract][Full Text] [Related]
3. Factors affecting 131I-Lym-1 pharmacokinetics and radiation dosimetry in patients with non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
DeNardo GL; DeNardo SJ; Shen S; DeNardo DA; Mirick GR; Macey DJ; Lamborn KR
J Nucl Med; 1999 Aug; 40(8):1317-26. PubMed ID: 10450684
[TBL] [Abstract][Full Text] [Related]
4. Imaging for improved prediction of myelotoxicity after radioimmunotherapy.
DeNardo DA; DeNardo GL; O'Donnell RT; Lim SM; Shen S; Yuan A; DeNardo SJ
Cancer; 1997 Dec; 80(12 Suppl):2558-66. PubMed ID: 9406710
[TBL] [Abstract][Full Text] [Related]
5. Body and blood clearance and marrow radiation dose of 131I-Lym-1 in patients with B-cell malignancies.
DeNardo GL; Mahe MA; DeNardo SJ; Macey DJ; Mirick GR; Erwin WD; Groch MW
Nucl Med Commun; 1993 Jul; 14(7):587-95. PubMed ID: 8355919
[TBL] [Abstract][Full Text] [Related]
6. Maximum tolerated dose of 67Cu-2IT-BAT-LYM-1 for fractionated radioimmunotherapy of non-Hodgkin's lymphoma: a pilot study.
Denardo GL; Denardo SJ; Kukis DL; O'Donnell RT; Shen S; Goldstein DS; Kroger LA; Salako Q; Denardo DA; Mirick GR; Mausner LF; Srivastava SC; Meares CF
Anticancer Res; 1998; 18(4B):2779-88. PubMed ID: 9713461
[TBL] [Abstract][Full Text] [Related]
7. Estimation of radiation absorbed doses to the red marrow in radioimmunotherapy.
Macey DJ; DeNardo SJ; DeNardo GL; DeNardo DA; Shen S
Clin Nucl Med; 1995 Feb; 20(2):117-25. PubMed ID: 7720301
[TBL] [Abstract][Full Text] [Related]
8. Milestones in the development of Lym-1 therapy.
DeNardo GL; O'Donnell RT; Rose LM; Mirick GR; Kroger LA; DeNardo SJ
Hybridoma; 1999 Feb; 18(1):1-11. PubMed ID: 10211782
[TBL] [Abstract][Full Text] [Related]
9. Maximum-tolerated dose, toxicity, and efficacy of (131)I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma.
DeNardo GL; DeNardo SJ; Goldstein DS; Kroger LA; Lamborn KR; Levy NB; McGahan JP; Salako Q; Shen S; Lewis JP
J Clin Oncol; 1998 Oct; 16(10):3246-56. PubMed ID: 9779698
[TBL] [Abstract][Full Text] [Related]
10. Prediction of myelotoxicity using radiation doses to marrow from body, blood and marrow sources.
Lim SM; DeNardo GL; DeNardo DA; Shen S; Yuan A; O'Donnell RT; DeNardo SJ
J Nucl Med; 1997 Sep; 38(9):1374-8. PubMed ID: 9293790
[TBL] [Abstract][Full Text] [Related]
11. Low-dose, fractionated radioimmunotherapy for B-cell malignancies using 131I-Lym-1 antibody.
DeNardo GL; DeNardo SJ; Lamborn KR; Goldstein DS; Levy NB; Lewis JP; O'Grady LF; Raventos A; Kroger LA; Macey DJ; McGahan JP; Mills SL; Shen S
Cancer Biother Radiopharm; 1998 Aug; 13(4):239-54. PubMed ID: 10850360
[TBL] [Abstract][Full Text] [Related]
12. Prediction of myelotoxicity using semi-quantitative marrow image scores.
Lim S; DeNardo GL; DeNardo DA; O'Donnell RT; Yuan A; DeNardo SJ
J Nucl Med; 1997 Nov; 38(11):1749-53. PubMed ID: 9374345
[TBL] [Abstract][Full Text] [Related]
13. Prediction of hematologic toxicity after radioimmunotherapy with (131)I-labeled anticarcinoembryonic antigen monoclonal antibodies.
Juweid ME; Zhang CH; Blumenthal RD; Hajjar G; Sharkey RM; Goldenberg DM
J Nucl Med; 1999 Oct; 40(10):1609-16. PubMed ID: 10520699
[TBL] [Abstract][Full Text] [Related]
14. Estimates of red marrow dose by sacral scintigraphy in radioimmunotherapy patients having non-Hodgkin's lymphoma and diffuse bone marrow uptake.
Juweid M; Sharkey RM; Siegel JA; Behr T; Goldenberg DM
Cancer Res; 1995 Dec; 55(23 Suppl):5827s-5831s. PubMed ID: 7493354
[TBL] [Abstract][Full Text] [Related]
15. A phase I study of 90Y-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma.
O'Donnell RT; Shen S; Denardo SJ; Wun T; Kukis DL; Goldstein DS; Denardo GL
Anticancer Res; 2000; 20(5C):3647-55. PubMed ID: 11268433
[TBL] [Abstract][Full Text] [Related]
16. Effect of Lym-1 radioimmunoconjugate on refractory chronic lymphocytic leukemia.
DeNardo GL; Lewis JP; DeNardo SJ; O'Grady LF
Cancer; 1994 Mar; 73(5):1425-32. PubMed ID: 8111709
[TBL] [Abstract][Full Text] [Related]
17. Phase I/II clinical radioimmunotherapy with an iodine-131-labeled anti-carcinoembryonic antigen murine monoclonal antibody IgG.
Behr TM; Sharkey RM; Juweid ME; Dunn RM; Vagg RC; Ying Z; Zhang CH; Swayne LC; Vardi Y; Siegel JA; Goldenberg DM
J Nucl Med; 1997 Jun; 38(6):858-70. PubMed ID: 9189130
[TBL] [Abstract][Full Text] [Related]
18. Correlation of red marrow radiation dosimetry with myelotoxicity: empirical factors influencing the radiation-induced myelotoxicity of radiolabeled antibodies, fragments and peptides in pre-clinical and clinical settings.
Behr TM; Béhé M; Sgouros G
Cancer Biother Radiopharm; 2002 Aug; 17(4):445-64. PubMed ID: 12396708
[TBL] [Abstract][Full Text] [Related]
19. A clinical trial of radioimmunotherapy with 67Cu-2IT-BAT-Lym-1 for non-Hodgkin's lymphoma.
O'Donnell RT; DeNardo GL; Kukis DL; Lamborn KR; Shen S; Yuan A; Goldstein DS; Carr CE; Mirick GR; DeNardo SJ
J Nucl Med; 1999 Dec; 40(12):2014-20. PubMed ID: 10616879
[TBL] [Abstract][Full Text] [Related]
20. Studies on the red marrow dosimetry in radioimmunotherapy: an experimental investigation of factors influencing the radiation-induced myelotoxicity in therapy with beta-, Auger/conversion electron-, or alpha-emitters.
Behr TM; Sgouros G; Stabin MG; Béhé M; Angerstein C; Blumenthal RD; Apostolidis C; Molinet R; Sharkey RM; Koch L; Goldenberg DM; Becker W
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3031s-3043s. PubMed ID: 10541340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
